← All trials
NCT02323113
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 19, 2015
- Primary completion
- May 16, 2020
- Completion date
- Nov 16, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 81
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Millennium PharmaceuticalsLead sponsor
- Millennium PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.